Clostridium difficile infection: New insights into therapeutic options

References

• Aas J, Gessert CE, Bakken JS. (2003). Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36:580–5
   PubMed Web of Science ®Google Scholar
• Aboudola S, Kotloff KL, Kyne L, et al. (2003). Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 71:1608–10
   PubMed Web of Science ®Google Scholar
• Abougergi MS, Kwon JH. (2011). Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Digest Dis Sci 56:19–26
   PubMed Web of Science ®Google Scholar
• Al-Nassir WN, Sethi AK, Li Y, et al. (2008). Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 52:2403–6
   PubMed Web of Science ®Google Scholar
• Baines SD, Freeman J, Wilcox MH. (2009). Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother 53:2202–4
   PubMed Web of Science ®Google Scholar
• Baines SD, O'Connor R, Freeman J, et al. (2008). Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 62:1046–52
   PubMed Web of Science ®Google Scholar
• Bakken JS, Borody T, Brandt LJ, et al. (2011). Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc 9:1044–9
   PubMed Web of Science ®Google Scholar
• Bartlett JG. (2002). Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 346:334–9
   PubMed Web of Science ®Google Scholar
• Bartlett JG. (2009). New antimicrobial agents for patients with Clostridium difficile infections. Curr Infect Dis Rep 11:21–8
   PubMedGoogle Scholar
• Bolton RP, Culshaw MA. (1986). Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27:1169–72
   PubMed Web of Science ®Google Scholar
• Buts JP. (2009). The probiotic Saccharomyces boulardii upgrades intestinal digestive functions by several mechanisms. Acta Gastroenterol Belg 72:274–6
   PubMed Web of Science ®Google Scholar
• Chang JY, Antonopoulos DA, Kalra A, et al. (2008). Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 197:435–8
   PubMed Web of Science ®Google Scholar
• Cohen SH, Gerding DN, Johnson S, et al. (2010). Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol: Off J Soc Hosp Epidemiol Am 31:431–55
   PubMed Web of Science ®Google Scholar
• Cornely OA, Crook DW, Esposito R, et al. (2012). Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12:281–9
   PubMed Web of Science ®Google Scholar
• Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. (2009). European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 15:1053–66
   PubMed Web of Science ®Google Scholar
• Debast SB, Bauer MP, Kuijper EJ. (2014). European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20:1–26
   PubMed Web of Science ®Google Scholar
• Drekonja DM, Butler M, MacDonald R, et al. (2011). Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med 155:839–47
   PubMed Web of Science ®Google Scholar
• Freeman J, Baines SD, Saxton K, Wilcox MH. (2007). Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 60:83–91
   PubMed Web of Science ®Google Scholar
• Ganeshapillai J, Vinogradov E, Rousseau J, et al. (2008). Clostridium difficile cell-surface polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate repeating units. Carbohydr Res 343:703–10
   PubMed Web of Science ®Google Scholar
• Gardiner DF, Rosenberg T, Zaharatos J, et al. (2009). A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine 27:3598–604
   PubMed Web of Science ®Google Scholar
• Garey KW, Ghantoji SS, Shah DN, et al. (2011). A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 66:2850–5
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV. (2013). Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 Gram-positive and Gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrob Agents Chemother 57:4872–6
   PubMed Web of Science ®Google Scholar
• Goorhuis A, Bakker D, Corver J, et al. (2008). Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 47:1162–70
   PubMed Web of Science ®Google Scholar
• Gough E, Shaikh H, Manges AR. (2011). Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53:994–1002
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Marbury TC, Foglia G, Warny M. (2012). Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 30:2245–9
   PubMed Web of Science ®Google Scholar
• Herpers BL, Vlaminckx B, Burkhardt O, et al. (2009). Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 48:1732–5
   PubMed Web of Science ®Google Scholar
• Hinkson PL, Dinardo C, DeCiero D, et al. (2008). Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile. Antimicrob Agents Chemother 52:2190–5
   PubMed Web of Science ®Google Scholar
• Jhung MA, Thompson AD, Killgore GE, et al. (2008). Toxinotype V Clostridium difficile in humans and food animals. Emerg Infect Dis 14:1039–45
   PubMed Web of Science ®Google Scholar
• Johnson AP, Wilcox MH. (2012). Fidaxomicin: a new option for the treatment of Clostridium difficile infection. J Antimicrob Chemother 67:2788–92
   PubMed Web of Science ®Google Scholar
• Karas JA, Enoch DA, Aliyu SH. (2010). A review of mortality due to Clostridium difficile infection. J Infect 61:1–8
   PubMed Web of Science ®Google Scholar
• Kazakova SV, Ware K, Baughman B, et al. (2006). A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 166:2518–24
   PubMedGoogle Scholar
• Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. (2010). Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 44:354–60
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Wasserman SS, Losonsky GA, et al. (2001). Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 69:988–95
   PubMed Web of Science ®Google Scholar
• Kuijper EJ, Barbut F, Brazier JS, et al. (2008). Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 13(31). pii: 18942
   Google Scholar
• Kuijper EJ, Coignard B, Tull P. (2006). Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12:2–18
   PubMed Web of Science ®Google Scholar
• Kyne L, Warny M, Qamar A, Kelly CP. (2000). Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342:390–7
   PubMed Web of Science ®Google Scholar
• Lamontagne F, Labbe AC, Haeck O, et al. (2007). Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 245:267–72
   PubMed Web of Science ®Google Scholar
• Leav BA, Blair B, Leney M, et al. (2010). Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28:965–9
   PubMed Web of Science ®Google Scholar
• Leffler DA, Lamont JT. (2009). Treatment of Clostridium difficile-associated disease. Gastroenterology 136:1899–912
   PubMed Web of Science ®Google Scholar
• Longo WE, Mazuski JE, Virgo KS, et al. (2004). Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 47:1620–6
   PubMed Web of Science ®Google Scholar
• Loo VG, Poirier L, Miller MA, et al. (2005). A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353:2442–9
   PubMed Web of Science ®Google Scholar
• Louie TJ, Cannon K, Byrne B, et al. (2012). Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 55:S132–42
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, et al. (2011). Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422–31
   PubMed Web of Science ®Google Scholar
• Louie TJ, Peppe J, Watt CK, et al. (2006). Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 43:411–20
   PubMed Web of Science ®Google Scholar
• McFarland LV, Elmer GW, Surawicz CM. (2002). Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97:1769–75
   PubMed Web of Science ®Google Scholar
• Miller M, Bernard L, Thompson M, et al. (2010). Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection. Infect Control Hosp Epidemiol: Off J Soc Hosp Epidemiol Am 31:710–5
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Bressler AM, et al. (2009). Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 48:e41–6
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Mehendiratta V, et al. (2007). Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 59:705–10
   PubMed Web of Science ®Google Scholar
• Neal MD, Alverdy JC, Hall DE, et al. (2011). Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 254:423–7; discussion 27–9
   PubMed Web of Science ®Google Scholar
• Nelson RL, Kelsey P, Leeman H, et al. (2011). Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. The Cochrane database of systematic reviews CD004610
   Google Scholar
• Ni Eidhin DB, O'Brien JB, McCabe MS, et al. (2008). Active immunization of hamsters against Clostridium difficile infection using surface-layer protein. FEMS Immunol Med Microbiol 52:207–18
   PubMedGoogle Scholar
• Numan SC, Veldkamp P, Kuijper EJ, et al. (2007). Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut 56:888–9
   PubMed Web of Science ®Google Scholar
• Oberli MA, Hecht ML, Bindschadler P, et al. (2011). A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem Biol 18:580–8
   PubMed Web of Science ®Google Scholar
• Pechine S, Deneve C, Le Monnier A, et al. (2011). Immunization of hamsters against Clostridium difficile infection using the Cwp84 protease as an antigen. FEMS Immunol Med Microbiol 63:73–81
   PubMedGoogle Scholar
• Pechine S, Janoir C, Collignon A. (2005). Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease. J Clin Microbiol 43:5018–25
   PubMed Web of Science ®Google Scholar
• Pepin J, Valiquette L, Alary ME, et al. (2004). Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171:466–72
   PubMed Web of Science ®Google Scholar
• Pepin J, Valiquette L, Cossette B. (2005). Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173:1037–42
   PubMed Web of Science ®Google Scholar
• Permpoonpattana P, Hong HA, Phetcharaburanin J, et al. (2011). Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun 79:2295–302
   PubMed Web of Science ®Google Scholar
• Pillai A, Nelson R. (2008). Probiotics for treatment of Clostridium difficile-associated colitis in adults. The Cochrane database of systematic reviews CD004611
   Google Scholar
• Razavi B, Apisarnthanarak A, Mundy LM. (2007). Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection 35:300–7
   PubMed Web of Science ®Google Scholar
• Rebeaud F, Bachmann MF. (2012). Immunization strategies for Clostridium difficile infections. Expert Review Vaccines 11:469–79
   PubMed Web of Science ®Google Scholar
• Rubin TA, Gessert CE, Aas J. (2009). Stool transplantation for older patients with Clostridium difficile infection. J Am Geriatr Soc 57:2386
   PubMed Web of Science ®Google Scholar
• Rupnik M, Wilcox MH, Gerding DN. (2009). Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7:526–36
   PubMed Web of Science ®Google Scholar
• Sears P, Crook DW, Louie TJ, et al. (2012). Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis 55:S116–20
   PubMed Web of Science ®Google Scholar
• Sougioultzis S, Kyne L, Drudy D, et al. (2005). Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128:764–70
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Brandt LJ, Binion DG, et al. (2013). Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108:478–98; quiz 99
   PubMed Web of Science ®Google Scholar
• Tannock GW, Munro K, Taylor C, et al. (2010). A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156:3354–9
   PubMed Web of Science ®Google Scholar
• Taylor NS, Bartlett JG. (1980). Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 141:92–7
   PubMed Web of Science ®Google Scholar
• van Dissel JT, de Groot N, Hensgens CM, et al. (2005). Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 54:197–205
   PubMed Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, et al. (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407–15
   PubMed Web of Science ®Google Scholar
• Vandenplas Y, Brunser O, Szajewska H. (2009). Saccharomyces boulardii in childhood. Eur J Pediatrics 168:253–65
   PubMed Web of Science ®Google Scholar
• Venugopal AA, Johnson S. (2012). Current state of Clostridium difficile treatment options. Clin Infect Dis 55:S71–6
   PubMed Web of Science ®Google Scholar
• Wenisch C, Parschalk B, Hasenhundl M, et al. (1996). Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 22:813–18
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Howe R. (1995). Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 36:673–9
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Planche T, Fang FC, Gilligan P. (2010). What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection? J Clin Microbiol 48:4347–53
   PubMed Web of Science ®Google Scholar
• Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. (2007). A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45:302–7
   PubMed Web of Science ®Google Scholar
• Zilberberg MD. (2009). Clostridium difficile-related hospitalizations among US adults, 2006. Emerg Infect Dis 15:122–4
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Shorr AF, Kollef MH. (2008). Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis 14:929–31
   PubMed Web of Science ®Google Scholar